BIAF
bioAffinity
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
BIAF Profile
Bioaffinity Technologies, Inc.
A company that develops proprietary noninvasive diagnostic tests and cancer therapeutics to diagnose early-stage cancer
Healthcare Equipment and Supplies
03/26/2014
09/01/2022
NASDAQ Stock Exchange
57
12-31
Common stock
22211 W Interstate 10, Suite 1206, San Antonio, Texas 78257
--
BioAffinity Technologies, Inc., was incorporated in Delaware on March 26, 2014. The company focuses on non-invasive diagnostic needs for early-stage cancer and lung diseases, and targets cancer therapy. The company has developed a proprietary platform for in vitro diagnostics, the first of which is a non-invasive test for early detection of lung cancer. The company's diagnostic tests are based on platform technologies that may be applicable to the detection of other lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma, as well as the diagnosis of cancer types such as prostate and bladder cancer.